These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27687970)

  • 1. Design, synthesis and evaluation of anti-CD123 antibody drug conjugates.
    Li B; Zhao W; Zhang X; Wang J; Luo X; Baker SD; Jordan CT; Dong Y
    Bioorg Med Chem; 2016 Nov; 24(22):5855-5860. PubMed ID: 27687970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The human polynucleotide kinase/phosphatase (hPNKP) inhibitor A12B4C3 radiosensitizes human myeloid leukemia cells to Auger electron-emitting anti-CD123 ¹¹¹In-NLS-7G3 radioimmunoconjugates.
    Zereshkian A; Leyton JV; Cai Z; Bergstrom D; Weinfeld M; Reilly RM
    Nucl Med Biol; 2014; 41(5):377-83. PubMed ID: 24637100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxicity Assessment and Apoptosis-related Gene Profiling of Antibody Treated Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) Cancerous Cell Lines.
    Habibi-Anbouhi M; Kafi Z; Ghazizadeh L; Kharazi S; Behdani M; Faraji F; Shokrgozar MA
    Iran J Allergy Asthma Immunol; 2019 Oct; 18(6):679-687. PubMed ID: 32245312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.
    Hutmacher C; Volta L; Rinaldi F; Murer P; Myburgh R; Manz MG; Neri D
    Leuk Res; 2019 Sep; 84():106178. PubMed ID: 31326578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells.
    Kovtun Y; Jones GE; Adams S; Harvey L; Audette CA; Wilhelm A; Bai C; Rui L; Laleau R; Liu F; Ab O; Setiady Y; Yoder NC; Goldmacher VS; Chari RVJ; Pinkas J; Chittenden T
    Blood Adv; 2018 Apr; 2(8):848-858. PubMed ID: 29661755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel immunoliposome mediated by CD123 antibody targeting to acute myeloid leukemia cells.
    Wang Y; Liu F; Wang Q; Xiang H; Jin H; Li H; Mao S
    Int J Pharm; 2017 Aug; 529(1-2):531-542. PubMed ID: 28583331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
    Han YC; Kahler J; Piché-Nicholas N; Hu W; Thibault S; Jiang F; Leal M; Katragadda M; Maderna A; Dushin R; Prashad N; Charati MB; Clark T; Tumey LN; Tan X; Giannakou A; Rosfjord E; Gerber HP; Tchistiakova L; Loganzo F; O'Donnell CJ; Sapra P
    Clin Cancer Res; 2021 Jan; 27(2):622-631. PubMed ID: 33148666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
    Han L; Jorgensen JL; Brooks C; Shi C; Zhang Q; Nogueras González GM; Cavazos A; Pan R; Mu H; Wang SA; Zhou J; Ai-Atrash G; Ciurea SO; Rettig M; DiPersio JF; Cortes J; Huang X; Kantarjian HM; Andreeff M; Ravandi F; Konopleva M
    Clin Cancer Res; 2017 Jul; 23(13):3385-3395. PubMed ID: 28096272
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of a new anti-CD123 monoclonal antibody to target the human CD123 antigen as an acute myeloid leukemia cancer stem cell biomarker.
    Abdollahpour-Alitappeh M; Razavi-Vakhshourpour S; Abolhassani M
    Biotechnol Appl Biochem; 2018 Nov; 65(6):841-847. PubMed ID: 29972607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
    Jin L; Lee EM; Ramshaw HS; Busfield SJ; Peoppl AG; Wilkinson L; Guthridge MA; Thomas D; Barry EF; Boyd A; Gearing DP; Vairo G; Lopez AF; Dick JE; Lock RB
    Cell Stem Cell; 2009 Jul; 5(1):31-42. PubMed ID: 19570512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia.
    Li F; Sutherland MK; Yu C; Walter RB; Westendorf L; Valliere-Douglass J; Pan L; Cronkite A; Sussman D; Klussman K; Ulrich M; Anderson ME; Stone IJ; Zeng W; Jonas M; Lewis TS; Goswami M; Wang SA; Senter PD; Law CL; Feldman EJ; Benjamin DR
    Mol Cancer Ther; 2018 Feb; 17(2):554-564. PubMed ID: 29142066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble Expression and Characterization of a New scFv Directed to Human CD123.
    Moradi-Kalbolandi S; Davani D; Golkar M; Habibi-Anbouhi M; Abolhassani M; Shokrgozar MA
    Appl Biochem Biotechnol; 2016 Apr; 178(7):1390-406. PubMed ID: 26749295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preparation of CD123 mono-antibody modified tanshinone ⅡA loaded immunoliposome and its in vitro evaluation].
    Wang Y; Liu FR; Xiang HL; Qing H; Chen C; Mao SJ; Li H
    Zhongguo Zhong Yao Za Zhi; 2017 Jun; 42(11):2085-2091. PubMed ID: 28822152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving anticancer activity and selectivity of camptothecin through conjugation with releasable substance P.
    Zhang W; Song J; Mu L; Zhang B; Liu L; Xing Y; Wang K; Li Z; Wang R
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1452-5. PubMed ID: 21282053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells.
    Fan D; Li Z; Zhang X; Yang Y; Yuan X; Zhang X; Yang M; Zhang Y; Xiong D
    J Hematol Oncol; 2015 Feb; 8():18. PubMed ID: 25879549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission.
    Xie LH; Biondo M; Busfield SJ; Arruda A; Yang X; Vairo G; Minden MD
    Blood Cancer J; 2017 Jun; 7(6):e567. PubMed ID: 28574487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia.
    Arcangeli S; Rotiroti MC; Bardelli M; Simonelli L; Magnani CF; Biondi A; Biagi E; Tettamanti S; Varani L
    Mol Ther; 2017 Aug; 25(8):1933-1945. PubMed ID: 28479045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population.
    Leyton JV; Hu M; Gao C; Turner PV; Dick JE; Minden M; Reilly RM
    J Nucl Med; 2011 Sep; 52(9):1465-73. PubMed ID: 21816968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues.
    Burke PJ; Senter PD; Meyer DW; Miyamoto JB; Anderson M; Toki BE; Manikumar G; Wani MC; Kroll DJ; Jeffrey SC
    Bioconjug Chem; 2009 Jun; 20(6):1242-50. PubMed ID: 19469529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation of a camptothecin prodrug with glutathione-responsive disulfide linker for anticancer drug delivery.
    Xu Z; Wang D; Xu S; Liu X; Zhang X; Zhang H
    Chem Asian J; 2014 Jan; 9(1):199-205. PubMed ID: 24136878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.